Pre-earnings brief
Reports
Thu, Nov 29, 2018
Est. EPS
—
Est. revenue
—
Implied move
±27.5%
EPS beat rate
50%
Zai Lab Limited is a biotechnology company focused on developing innovative therapies for cancer and autoimmune diseases. Operating in the healthcare sector, it plays a crucial role in addressing unmet medical needs, particularly in the Asian market.
Last quarter
In Q2 2026, Zai Lab reported an EPS of -$0.46, which was consistent with previous quarters. The stock saw a positive reaction, gaining 13.66% the following day.
EPS beat streak
0Q
EPS beat rate
50%
Avg EPS surprise
+3.86%
Avg 1-day reaction
-1.93%
Investors are cautiously optimistic about Zai Lab's upcoming earnings, particularly given the recent stock performance. However, the lack of analyst estimates adds uncertainty.
Bull case
If Zai Lab can demonstrate improved revenue and potentially narrow its losses, it could signal a turnaround and attract more investor interest.
Bear case
Conversely, if the company reports wider losses or disappointing revenue, it may lead to further declines in stock price and investor confidence.
The print will turn on these.
Q1
What is the expected revenue for this quarter?
Revenue figures will be critical in assessing the company's growth trajectory and market demand.
Q2
How does Zai Lab plan to address its ongoing losses?
Management's strategy for improving profitability will be closely scrutinized by investors.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Why consensus could be wrong
The Street may underestimate Zai Lab's potential for revenue growth due to recent product developments that have not been fully factored into forecasts.
Supporting evidence
The stock has shown resilience with a 13.66% gain following the last earnings report, indicating investor optimism.
The options market is pricing in a significant move, suggesting that traders expect volatility that could favor a positive outcome.
Key risk
If revenue growth exceeds expectations, it could lead to a reassessment of the company's market position.
Pre-commit to what would confirm each case.
This quarter, the focus will be on revenue growth and management's plan for addressing ongoing losses, which are critical for investor confidence.
Bull confirmed if
A revenue increase of at least 15% compared to the previous quarter would confirm the bull case.
Bear confirmed if
Wider losses than expected, particularly if EPS falls below -$0.50, would confirm the bear case.
What the market is pricing for the move.
Implied Move
±31.61%
Historical Avg
±6.4%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.
Options are pricing ±27.5% while ZLAB has averaged ±6.4% over the last 8 prints — setup is pricing rich.
ATM IV
1.6%
30d HV
42.8%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Zai Lab beats expectations, history suggests a potential stock increase of around 6.42%, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may see a muted reaction as investors await further clarity from management.
Miss
Should the company miss expectations, history indicates a potential decline of about 2.36%, which could raise concerns about future performance.
The lines on the call that would change the story.